TISSUE REGENIX GROUP PLC ORD GBP0.001TISSUE REGENIX GROUP PLC ORD GBP0.001TISSUE REGENIX GROUP PLC ORD GBP0.001

TISSUE REGENIX GROUP PLC ORD GBP0.001

No trades
See on Supercharts

TRX fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. It operates through the BioSurgery, Orthopaedics, Cardiac and Other divisions. Its patented decellularisation technology removes DNA and other cellular material from animal and human tissue leaving a cellular tissue scaffold, which is not rejected by the patient's body and can then be used to repair diseased and worn out body parts. The company was founded by Eileen Ingham and John Fisher in May 2006 and is headquartered in Leeds, the United Kingdom.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

TRX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company